Gsk (GSK) Liabilities and Shareholders Equity (2009 - 2026)

Gsk's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $82.8 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 4.78% year-over-year to $82.8 billion; the TTM figure through Jun 2026 stood at $331.7 billion (up 7.94% YoY), while the FY2025 annual figure was $80.6 billion, up 6.02% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $82.8 billion, down from $84.8 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $112.1 billion in Q2 2022, with the low at $60.4 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $75.9 billion (2024), against an average of $77.6 billion.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity tumbled 43.89% in 2022, then increased 17.89% in 2023.
• Gsk's Liabilities and Shareholders Equity stood at $70.5 billion in 2022, then advanced by 3.81% to $73.2 billion in 2023, then increased by 4.21% to $76.3 billion in 2024, then climbed by 6.52% to $81.3 billion in 2025, then advanced by 1.89% to $82.8 billion in 2026.
• Business Quant data shows GSK's Liabilities and Shareholders Equity at $82.8 billion in Q2 2026, $84.8 billion in Q1 2026, and $81.3 billion in Q4 2025.